Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.73 |
| ▸ | PON1 | P27169 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | GLA | P06280 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.65 |
| ▸ | P4HB | P07237 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 7/20 | 0.57 |
| ▸ | CA9 | Q16790 | 7/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28065506 | 0.84 | MCL1 (1.00) | MCL1PON1KDM4EALDH1A1GLA | |
| SCHEMBL15984890 | 0.84 | KDM4E (0.64) | KDM4EALDH1A1GLAHPGDMAOB | |
| SCHEMBL15211418 | 0.83 | MCL1 (0.75) | MCL1PON1KDM4EALDH1A1GLA | |
| SCHEMBL7000517 | 0.82 | KDM4E (0.70) | MCL1KDM4EALDH1A1GLAHPGD | |
| SCHEMBL15211432 | 0.81 | MCL1 (0.68) | MCL1PON1KDM4EALDH1A1GLA | |
| SCHEMBL876290 | 0.81 | KDM4E (0.64) | MCL1PON1KDM4EALDH1A1GLA | |
| SCHEMBL5345045 | 0.80 | MAOB (0.77) | MCL1KDM4EALDH1A1GLAHPGD | |
| SCHEMBL15104536 | 0.80 | KDM4E (0.60) | MCL1PON1KDM4EALDH1A1GLA | |
| SCHEMBL15104539 | 0.80 | KDM4E (0.63) | MCL1PON1KDM4EALDH1A1GLA | |
| SCHEMBL18074001 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1GLAHPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838891-B1 | AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-3196274-A1 | SULFONATED COUMARINS, SYNTHESIS THEREOF, AND USES THEREOF | Etablissements J. Soufflet (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3196274-A1 | SULFONATED COUMARINS, SYNTHESIS THEREOF, AND USES THEREOF | Etablissements J. Soufflet (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-2619281-B1 | SULFONATED COUMARINS, SYNTHESIS THEREOF, FLUOROGENIC SUBSTRATES RESULTING FROM GRAFTING SAID COUMARINS ONTO SUGARS, METHOD FOR PREPARING SAID SUBSTRATES, AND USES THEREOF | J SOUFFLET ETS (FR) | 2016-11-09 | — | — | EP | disclosed |
| CN-104254525-B | aromatic ring compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| US-9238639-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2646425-B1 | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2838891-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-25 | — | — | EP | disclosed |
| CN-104254525-A | Aromatic ring compound | TAKEDA PHARMACEUTICAL | 2014-12-31 | — | — | CN | disclosed |
| US-20140234884-A1 | FLUOROGENIC SUBSTRATES, METHODS OF MAKING THE SUBSTRATES, AND METHODS OF DETECTING GLYCOSIDASE ACTIVITIES | UNIVERSITE DE STRASBOURG (FR) | 2014-08-21 | — | — | US | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012038614-A1 | SULFONATED COUMARINS, SYNTHESIS THEREOF, FLUOROGENIC SUBSTRATES RESULTING FROM GRAFTING SAID COUMARINS ONTO SUGARS, METHOD FOR PREPARING SAID SUBSTRATES, AND USES THEREOF | ETS J. SOUFFLET (FR) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038614-A1 | SULFONATED COUMARINS, SYNTHESIS THEREOF, FLUOROGENIC SUBSTRATES RESULTING FROM GRAFTING SAID COUMARINS ONTO SUGARS, METHOD FOR PREPARING SAID SUBSTRATES, AND USES THEREOF | ETS J. SOUFFLET (FR) | 2012-03-29 | — | — | WO | disclosed |
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234884-A1 | FLUOROGENIC SUBSTRATES, METHODS OF MAKING THE SUBSTRATES, AND METHODS OF DETECTING GLYCOSIDASE ACTIVITIES | ENGASE, GBA3, GMDS | MCL1 1511/4885PON1 511/4885KDM4E 1348/4885 |
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | MCL1 1419/4885PON1 2221/4885KDM4E 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.